<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01333150</url>
  </required_header>
  <id_info>
    <org_study_id>M-20090062</org_study_id>
    <nct_id>NCT01333150</nct_id>
  </id_info>
  <brief_title>Effect of Propranolol on the Autonomic Nervous System and Muscle Pain</brief_title>
  <official_title>Effects of a Low-dose Propranolol on a Stress Induced Autonomic Response and on Muscle Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The project's primary purpose is to test the hypothesis that oral administration of a low
      single dose of Î²-antagonist propranolol (40 mg) reduces pain sensitivity in patients with
      masticatory muscle pain.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">September 2012</completion_date>
  <primary_completion_date type="Anticipated">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain intensity</measure>
    <time_frame>Participants will be asked to score their actual pain level in both of the two experimental sessions they will participate in; an expected average of two weeks between the two sessions</time_frame>
    <description>Numeric Rating Scale 0-10</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Haemodynamic parameters</measure>
    <time_frame>Participants will be monitored during the entire session in both of the two experimental sessions they will participate in; an expected average of two weeks between the two sessions</time_frame>
    <description>Monitoring of pulse and blodpressurevariability, respiration, baroreceptor sensitivity, measured non-invasively by Task Force Monitor.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Temporomandibular Joint Disorders</condition>
  <condition>Myofascial Temporomandibular Disorders</condition>
  <arm_group>
    <arm_group_label>Propranolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranololhydrochlorid</intervention_name>
    <description>One single dose of Propranolol tablet of 40 mg randomized in one of the two sessions</description>
    <arm_group_label>Propranolol</arm_group_label>
    <other_name>Propranolol &quot;DAK&quot; 40 mg, Nycomed Denmark ApS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One single dose of placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD) for
             myofascial TMD diagnosis corresponding to group 1a or 1b

          -  Characteristic Pain Intensity (CPI) more than or equal to 20 (Axe II, RDC/TMD
             questionnaire)

          -  Women of childbearing potential must use adequate contraception

          -  Signed consent statement

        Exclusion Criteria:

          -  Other acute pain cause such as acute toothache or a pain condition the investigator
             estimates to be contraindicated for participation in the experiment

          -  Recognized existing malignancy or within last 5 years

          -  Known HIV

          -  Abuse of drugs including alcohol

          -  Recognized Raynaud's syndrome

          -  Former sympathectomy

          -  Known cardiovascular disease including abnormal EKG and blood pressure (ECG-12 is
             recorded before the first trial session and assessed by the physician)

          -  Recognized lung insufficience, including bronchial asthma

          -  Known severe hepatic or renal dysfunction

          -  Known diabetes mellitus

          -  Known severe depression

          -  Pregnancy (tests performed in both sessions 1 and 2 before the start of a session)

          -  Fertility Treatment

          -  Lactation

          -  Post-menopausal

          -  Previous adverse reaction when taking beta-blocker, including hypersensitivity to
             propranolol or to any of the excipients

          -  Patients who can not read and understand the written information

          -  Patients who can not follow the protocol

          -  Patients who do not agree to comply with the requirements for participation in both
             studies regarding food intake, physical activity, etc.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Svensson, DDS, PhD, Dr.Odont</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Aarhus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karina H. Bendixen, DDS, PhD fellow</last_name>
    <phone>+004587168259</phone>
    <email>karina.bendixen@odontologi.au.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Section of Clinical Oral Physiology, Aarhus University</name>
      <address>
        <city>Aarhus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karina H. Bendixen, PhD fellow</last_name>
      <phone>+004587168259</phone>
      <email>karina.bendixen@odontologi.au.dk</email>
    </contact>
    <investigator>
      <last_name>Peter Svensson, DDS, PhD, Dr.Odont.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karina H. Bendixen, DDS, PhD fellow</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Section of Clinical Oral Physiology,Department of Dentistry,HEALTH. Aarhus University</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Karina Bendixen, DDS, PhD fellow</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2011</study_first_submitted>
  <study_first_submitted_qc>April 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2011</study_first_posted>
  <last_update_submitted>March 23, 2012</last_update_submitted>
  <last_update_submitted_qc>March 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Temporomandibular disorders</keyword>
  <keyword>Orofacial pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Temporomandibular Joint Disorders</mesh_term>
    <mesh_term>Temporomandibular Joint Dysfunction Syndrome</mesh_term>
    <mesh_term>Joint Diseases</mesh_term>
    <mesh_term>Myalgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

